ENYO PHARMA
ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public). The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and the BSL4 laboratory Inserm-Jean Mérieux. ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and devel... oped a unique platform for the identification of intracellular therapeutic targets and molecules. The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials.
ENYO PHARMA
Industry:
Biopharma Biotechnology Medical
Founded:
2014-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.enyopharma.com
Total Employee:
11+
Status:
Active
Contact:
33437700219
Email Addresses:
[email protected]
Total Funding:
64.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Investors List
InnoBio
InnoBio investment in Series B - ENYO Pharma
Bpifrance
Bpifrance investment in Series B - ENYO Pharma
Morningside Venture Investments
Morningside Venture Investments investment in Series B - ENYO Pharma
OrbiMed
OrbiMed investment in Series B - ENYO Pharma
Sofinnova Investments
Sofinnova Investments investment in Series B - ENYO Pharma
Inserm Transfert Initiative
Inserm Transfert Initiative investment in Series B - ENYO Pharma
Andera Partners
Andera Partners investment in Series B - ENYO Pharma
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - ENYO Pharma
Sofinnova Partners
Sofinnova Partners investment in Series A - ENYO Pharma
Official Site Inspections
http://www.enyopharma.com Semrush global rank: 8.82 M Semrush visits lastest month: 249
- Host name: 98-116-176-185.rev.solware.fr
- IP address: 185.116.176.98
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "ENYO Pharma" on Search Engine
about_us – ENYO Pharma
News. Latest Press Release. ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome. ENYO Pharma announ... > Read more.See details»
Management – ENYO Pharma
ENYO Pharma - Crunchbase Company Profile & Funding
ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).See details»
ENYO Pharma's Board of Directors - Team members and org …
The Org. helps you hire. great candidates. ENYO Pharma's Board of Directors includes Timothy M. Wright and 8 others.See details»
ENYO Pharma | LinkedIn
ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function.See details»
ENYO Pharma Announces a €39 Million Series C …
Jan 3, 2024 ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome. The Company will initiate a Phase 2...See details»
ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top …
Jul 30, 2021 The ENYO founding team discovered that FXR agonists interfere with interactions between FXR and HBx, a hepatitis B viral protein essential for virus replication.See details»
ENYO Pharma - Contacts, Employees, Board Members, Advisors …
ENYO Pharma has 9 current employee profiles, including Founder, President and CEO Jacky Vonderscher. ENYO Pharma has 12 board members and advisors, including Jacky Vonderscher.See details»
Enyo Pharma's NASH results show boost in kidney function ...
Jul 28, 2021 Enyo Pharma’s liver disease drug reduced liver fat and boosted kidney health during a mid-stage clinical trial, meeting its main and secondary goals while supporting the design of next stage...See details»
ENYO Pharma - Funding, Financials, Valuation & Investors
ENYO Pharma has raised a total of. €103.5M. in funding over 4 rounds. Their latest funding was raised on Jan 3, 2024 from a Series C round. ENYO Pharma is funded by 11 investors. Bpifrance Large Venture and Bpifrance InnoBio are …See details»
ENYO Pharma - Updates, News, Events, Signals & Triggers
Research and Development Insight Details. Powered by AI. ENYO Pharma is focused on developing therapeutic agents with a synergistic approach, as evidenced by their research into combining FXR agonists with TLR3 agonists for disease treatment.See details»
ENYO Pharma Announces a €39 Million Series C Financing and …
Jan 3, 2024 The clearance of ENYO’s IND represents a significant milestone for the company as it embarks on its first clinical trial focusing on renal disease. ENYO’s lead candidate Vonafexor, as well as fast follower EYP651, are highly specific FXR agonists given as once-daily oral treatments.See details»
Series C - ENYO Pharma - 2024-01-03 - Crunchbase
Jan 4, 2024 The Bakersfield Californian — ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport SyndromeSee details»
ENYO Pharma SA - Drug pipelines, Patents, Clinical trials
May 1, 2024 Explore ENYO Pharma SA with its drug pipeline, therapeutic area, technology platform, 14 clinical trials, 5 news, and 1 literature, Disease Domain:Infectious Diseases, Technology Platform:Small molecule drug, Drug:Tenofovir disoproxil hemiedisylate, Vonafexor, EYP-002.See details»
Enyo Pharma (France) Funding: €103.5M - Medical Startups
May 4, 2024 ENYO Pharma is a clinical stage Biotech with a unique drug discovery engine inspired by viruses. In particular it develops drug for Chronic Hepatitis B.See details»
ENYO Pharma - Overview, News & Similar companies - ZoomInfo
Nov 4, 2021 Who is ENYO Pharma. ENYO is a clinical-stage biopharmaceutical company headquartered in Lyon (France) and developing proprietary drug candidates to improve quality of life and avoid end stage renal disease and dialysis for patients with rare and common kidney diseases. Read more. ENYO Pharma's Social MediaSee details»
About us – ENYO Pharma
About us. Company overview. Founders. Management. Board. Investors. Latest Press Release. ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome.See details»
Vonafexor - ENYO Pharma - AdisInsight - Springer
Jan 16, 2024 If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely. IP authentication when working within your organization’s network.See details»
WHO emergencies team faces funding crunch as health crises …
1 day ago The World Health Organization's emergencies department is facing “existential threats” as multiplying health crises have left it so short of cash that it needed emergency funds to pay staff ...See details»
Dengue cases in Americas surpass last year's record high, WHO …
1 day ago Dengue cases have substantially increased in the Americas this year, the World Health Organization (WHO) said on Thursday, which indicates the mosquito-borne viral illness remains a high-risk ...See details»